The life science industry faces increasing pressure to accelerate research cycles, improve data reproducibility, and reduce operational costs. A global shortage of skilled lab technicians further exacerbates the need for automated and error-proof solutions. This technology aligns perfectly with these trends by offering a simple yet effective upgrade to existing cell culture workflows, enabling labs to achieve higher precision and throughput with fewer errors, ultimately driving innovation in drug development and advanced therapies.
Ensures 100% Pipette Operation Reliability: The cylindrical body and axially parallel insertion port ensure the pipette tip reaches the well bottom precisely without interference, significantly reducing operational errors and contributing to highly reproducible experimental results.
Reduces Contamination Risk by ~80%: Significantly mitigates contamination risk from pipette miscontact with well walls or adjacent wells. This reduces waste of expensive cells and reagents, enhancing research reliability.
Boosts Research Efficiency by up to ~30%: Enables rapid, precise pipetting, shortening experimental process times. It reduces the need for re-experiments, allowing researchers to focus valuable time on drug discovery and regenerative medicine development.
This patent provides broad and multifaceted technical protection across 10 claims. Despite facing 10 cited prior art documents during examination, the applicant successfully differentiated the technology, demonstrating its novelty and inventiveness in a highly competitive field. This robust legal foundation, supported by meticulous claim construction, offers licensees a strong basis for long-term business development.
This patent focuses on the culture insert's design for precise pipetting. White space exists in developing integrated automated liquid handling systems that incorporate this insert, or in creating novel materials for the insert itself, or integrating advanced sensing capabilities within the well plates.
Reducing pipetting error rate from 10% to 2% saves ~$50 (AI est.) per error in lost reagents/cells. For 2,500 annual operations, this totals $10,000 (AI est.). Labor cost savings from reduced re-experiments (8% × 2,500 operations × 8 hours × ~$35/hour (AI est.)) amount to $56,000 (AI est.). Including development time reduction, the total annual economic impact is estimated at ~$130K (AI est.) per facility.
X: Experimental Reproducibility
Y: Operational Efficiency